Results 241 to 250 of about 14,066,519 (402)

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

A personal perspective of patient-centred clinical trials. [PDF]

Oncotarget
Tyne T, Ivimey E, Duggan L, Liu J.
europepmc   +1 more source

Protocol for the process evaluation of a randomised clinical trial of incremental-start versus conventional haemodialysis: the TwoPlus study

Mariana Murea, Kristie L. Foley, Samir C. Gautam, Jennifer E. Flythe, Jochen G. Raimann, Emaad M. Abdel‐Rahman, Alaa S. Awad, Vandana Dua Niyyar, Cassandra Kovach, Glenda V. Roberts, N Jefferson, Paul T. Conway, Laura Rosales, Jobira A. Woldemichael, Hiba I Sheikh, Gaurav Raman, Anne M. Huml, Daphne H. Knicely, Irtiza Hasan, Bhaktidevi Makadia, Janice P. Lea, John T. Daugirdas, Nihan Gencerliler, Jasmin Divers, Peter Kotanko, Alexandra Peluso, Denisse A. Funes, Fatima Ezzahra Salmi, Erica J. Trembath, Lyn B. Lyman, Harvey Maute, Jessica Guillaume, Victoria Shoyelu, E. Rezaei Ghalechi, Erika Adams, Jessica Farrell, Nancy Ginsberg, Christa Howard, Suzanne Shabdue, Shawanna Jackson, Seth Johnson, Randall D. Blackie, Sheetal Chaudhuri, Priya Desai, Kristy L. Hamilton, Igor Shumilin, Diana Clynes, Valerie Gonzalez, Erin Kahle, Brindusa Burciu, Lela Tisdale, K. Vergara, Lin‐Chun Wang, R. Jose Varghese, Rendy Chaparros, Xu Wang, Emily K. Burns, M. C. Abrams, Marina Marković, Maxim Yeremenko, Caroline J. Poulton, Amanpreet Singh, Katlyn Stiles, Ashleigh Trapuzzano, Joni Baker, Susan Trynosky, Ucheoma Nwaozuru   +66 more
openalex   +1 more source

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Journal of Clinical Oncology, 2016
H. Scher, M. Morris, W. Stadler, C. Higano, E. Basch, K. Fizazi, E. Antonarakis, T. Beer, M. Carducci, K. Chi, P. Corn, J. D. de Bono, R. Dreicer, D. George, E. Heath, M. Hussain, W. Kelly, Glenn Liu, C. Logothetis, D. Nanus, M. Stein, D. Rathkopf, S. Slovin, C. Ryan, O. Sartor, E. Small, Matthew R. Smith, C. Sternberg, M. Taplin, G. Wilding, P. Nelson, L. Schwartz, S. Halabi, P. Kantoff, A. Armstrong   +34 more
semanticscholar   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

AXL Inhibitors in Oncology Clinical Trials: A Review. [PDF]

J Immunother Precis Oncol
Quach E, Sanginova F, Cheruku A, Stack S, Falchook GS.   +4 more
europepmc   +1 more source

Comparative Evaluation of Subgingivally Delivered Titanium Prepared Platelet Rich Fibrin (T-PRF) and Tetracycline Fibers as an Adjunct to Scaling and Root Planning in Treatment of Periodontitis: A Randomized Controlled Clinical Trial

Chirag Gupta, Swati Agarwal, Ellora Madan, Kratee Sharma, Nuzla Agha, Karnika Agrawal   +5 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Landscape of paediatric oncology clinical trials in Asia. [PDF]

EClinicalMedicine
Khan MS, Tomizawa D, Zheng H, Saha V, Ariffin H, Hori H, Arora RS, Tamamyan G, Aisyi M, Kurkure P, Agarwal B, Yu AL, Dalvi R, Kirgizov K, Chen BW, Seksarn P, Nakagawara A, Chan GCF, Arakawa A, Gao Y, Krishnan S, Yeoh AEJ, Luo XQ, Zhu XF, Manabe A, Li CK.   +25 more
europepmc   +1 more source

An AI Virtual Team of Coordinated Agents for Exploratory Clinical Trial Data Analysis

Geybels, Milan
openalex   +1 more source